Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects

• Status: Active, not recruiting
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ivonne Schulman; Joshua M Hare
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Criteria

Inclusion Criteria:

• Be ≥ 21 and < 90 (inclusive) years of age.

• Provide written informed consent.

• Have endothelial dysfunction defined by impaired flow-mediated vasodilation (FMD <7%).

• Have an ejection fraction > 45% by gated blood pool scan, two- dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the prior 3 months.

• Have Diabetes mellitus type 2 documented by hemoglobin adult type 1 component (A1C) > 7% or on medical therapy for diabetes.

• Females of childbearing potential must use two forms of birth control for the duration of the study. Female subjects must undergo a blood or urine pregnancy test at screening and within 36 hours prior to infusion.

Exclusion Criteria:

In order to participate in this study, a subject Must Not:

• Be younger than 21 years or older than 90 years of age.

• Have a baseline glomerular filtration rate <35 ml/min 1.73m^2 estimated using the Modification of Diet in renal disease (MDRD) formula.

• Have an ejection fraction <45% by gated blood pool scan, two-dimensional echocardiogram, cardiac MRI, cardiac CT or left ventriculogram within the past year, as documented by medical history.

• Have poorly controlled blood glucose levels with hemoglobin A1C > 8.5%.

• Have a history of proliferative retinopathy or severe neuropathy requiring medical treatment.

• Have a hematologic abnormality as evidenced by hematocrit < 25%, white blood cell < 2,500/ul or platelet values < 100,000/ul without another explanation.

• Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal.

• Have a bleeding diathesis or coagulopathy (INR > 1.3), cannot be withdrawn from anticoagulation therapy, or will refuse blood transfusions.

• Have Lymphadenectomy or Lymph node dissection in the right arm.

• Be an organ transplant recipient or have a history of organ or cell transplant rejection.

• Have a clinical history of malignancy within the past 5 years (i.e., subjects with prior malignancy must be disease free for 5 years), except curatively- treated basal cell or squamous cell carcinoma, or cervical carcinoma.

• Have a condition that limits lifespan to < 1 year.

• Have a history of drug or alcohol abuse within the past 24 months.

• Be on chronic therapy with immunosuppressant medication, such as corticosteroids or Tumor Necrosis Factor - alpha (TNFα) antagonists.

• Be serum positive for HIV, Syphilis - VDRL (Confirmation with FTA-ABS if needed (Syphilis)), hepatitis B surface antigen or viremic hepatitis C.

• Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.

• Be pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.

• Any other condition that in the judgment of the Investigator would be a contraindication to enrollment or follow-up.